Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients

• Published in: Clinical and experimental medicine 2016-05, Vol.16 (2), p.193-202
• Main Authors: Paredes-Turrubiarte, Gabriela, González-Chávez, Antonio, Pérez-Tamayo, Ruy, Salazar-Vázquez, Beatriz Y., Hernández, Vito S., Garibay-Nieto, Nayeli, Fragoso, José Manuel, Escobedo, Galileo
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Female; Hematology; Humans; Inflammation; Interleukin-10 - blood; Internal Medicine; Liver - diagnostic imaging; Liver diseases; Liver Function Tests; Male; Medicine; Medicine & Public Health; Middle Aged; Non-alcoholic Fatty Liver Disease - pathology; Obesity; Obesity, Morbid - complications; Oncology; Original Article; Serum - chemistry; Severity of Illness Index; Tumor Necrosis Factor-alpha - blood; Tumors; Ultrasonography; Young Adult
• ISSN: 1591-9528; 1591-8890; 1591-9528
• DOI: 10.1007/s10238-015-0347-4

Morbid obesity has been shown to increase the risk to develop hepatic steatosis, also referred to as non-alcoholic fatty liver disease (NAFLD). Emerging evidence suggests that the severity of NAFLD may associate with increased serum levels of inflammatory markers as well as decreased concentration of mediators with anti-inflammatory actions, such as tumor necrosis factor alpha (TNF-α) and interleukin (IL) 10, respectively. We thus examined the serum levels of TNF-α and IL-10 in 102 morbidly obese women and men (body mass index > 40 kg/m 2 ), exhibiting different grades of NAFLD. Blood glucose, glycated hemoglobin, insulin, the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, triglycerides, high- and low-density lipoproteins, parameters of liver function, TNF-α, and IL-10 were measured in each subject. The stage of NAFLD was estimated by abdominal ultrasound imaging. In comparison with morbidly obese subjects without steatosis, morbidly obese patients with NAFLD showed increased age (39.23 ± 9.80 years), HOMA-IR (6.74 ± 1.62), total cholesterol (219.7 ± 9.58 mg/dl), aspartate aminotransferase (36.25 ± 3.24 UI/l), gamma-glutamyl transpeptidase (37.12 ± 3.41 UI/l), and TNF-α (37.41 ± 1.72 pg/ml) as well as decreased serum levels of IL-10 (61.05 ± 2.43 pg/ml). Interestingly, the systemic levels of TNF-α increased, while IL-10 decreased in accordance with the severity of NAFLD, which supports a role for systemic inflammatory mediators in promoting steatosis progression. Further clinical prospective studies need to be addressed to elucidate the role of TNF-α and IL-10 in the development of NAFLD while also establishing their clinical utility in the assessment of morbidly obese patients at higher risk to develop severe steatosis.